Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Authors
Keywords
-
Journal
BLOOD
Volume 124, Issue 26, Pages 3870-3879
Publisher
American Society of Hematology
Online
2014-10-31
DOI
10.1182/blood-2014-03-563627
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
- (2014) David A. Rizzieri et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
- (2013) T. Wasterlid et al. ANNALS OF ONCOLOGY
- Suboptimal dosing of rituximab in male and female patients with DLBCL
- (2013) M. Pfreundschuh et al. BLOOD
- Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
- (2013) L. J. Costa et al. BLOOD
- Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database
- (2013) Jorge J. Castillo et al. CANCER
- High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program
- (2013) T. Intermesoli et al. HAEMATOLOGICA
- Low-Intensity Therapy in Adults with Burkitt's Lymphoma
- (2013) Kieron Dunleavy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
- (2012) Yvette L. Kasamon et al. LEUKEMIA & LYMPHOMA
- Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
- (2011) J. A. Barnes et al. ANNALS OF ONCOLOGY
- RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma
- (2011) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial
- (2011) Torben S. Mikkelsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- Intrathecal Vincristine
- (2009) Bernadette Hennipman et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
- (2008) G. M. Mead et al. BLOOD
- High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma
- (2008) Albert Oriol et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started